Shah, Neil PGarcia-Gutierrez, ValentinJimenez-Velasco, AntonioLarson, SarahSaussele, SusanneRea, DelphineMahon, François-XavierLevy, Moshe YairGomez-Casares, Maria TeresaPane, FabrizioNicolini, Franck-EmmanuelMauro, Michael JSy, OumarMartin-Regueira, PatriciaLipton, Jeffrey H2023-02-082023-02-082019-10-24Shah, N. P., García-Gutiérrez, V., Jiménez-Velasco, A., Larson, S., Saussele, S., Rea, D., et al. Dasatinib discontinuation in patients with chronic-phase chronic myeloid leukemia and stable deep molecular response: the DASFREE study. Leukemia & Lymphoma/Leukemia And Lymphoma, 61(3), 650-659http://hdl.handle.net/10668/15255Treatment-free remission (TFR) in patients with chronic myeloid leukemia in chronic phase (CML-CP) is considered a feasible option, especially with the ability of second-generation tyrosine kinase inhibitors to induce higher rates of sustained deep molecular response (DMR). DASFREE is an open-label, single-arm, multicenter phase II trial assessing TFR after dasatinib discontinuation in patients with CML-CP (N = 84). At 2 years, TFR was 46% in all patients. Multivariate analyses revealed statistically significant associations between 2-year TFR and duration of prior dasatinib (≥median; p = .0051), line of therapy (first line; p = .0138), and age (>65 years; p = .0012). No disease transformation occurred, and the most common adverse events experienced off treatment were musculoskeletal (observed in 30 patients); however, dasatinib withdrawal events were reported in nine patients (11%) by the investigator. Overall, these findings support the feasibility of discontinuing dasatinib for patients with CML-CP in sustained DMR in the first line and beyond.enAttribution 4.0 Internationalhttp://creativecommons.org/licenses/by/4.0/CML-CPDasatinibDeep molecular responseImatinibMajor molecular responseTreatment-free remissionAgedDasatinibHumansLeukemia, Myelogenous, Chronic, BCR-ABL PositiveLeukemia, Myeloid, Chronic-PhaseProtein Kinase InhibitorsTreatment Outcomeresearch article31647335open accessAptitudAnálisis MultivarianteInhibidores de la Tirosina Proteína QuinasaLeucemia Mielógena Crónica BCR-ABL Positiva10.1080/10428194.2019.16758791029-2403https://www.tandfonline.com/doi/pdf/10.1080/10428194.2019.1675879?needAccess=true